Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix is viewed favorably because AXPAXLI combines a de-risked regulatory path with a differentiated wet AMD profile, including a prespecified Phase 3 superiority result against an approved anti-VEGF and a positive Pre-NDA meeting that left the submission package unchanged. Its core investment case rests on potentially industry-leading 9-12Mth durability, which could separate it from anti-VEGF rivals and support stronger access and reimbursement dynamics if approved under the 505(b)(2) pathway. The outlook is further supported by multiple FDA interactions with zero changes to the package and visible catalysts in 4Q26 and 1Q27, while HELIOS-3 adds a second value driver.

Ocular Therapeutix is viewed negatively because its investment case is highly concentrated in Axpaxli, a Phase 3 asset whose U.S. commercialization still depends on FDA approval, an acceptable NDA package, and a favorable label for 6-12 month dosing. Even with positive Phase 3 SOL-1 data, regulatory agencies could demand more evidence, while competition from established anti-VEGF therapies and reimbursement or physician-acceptance hurdles could limit uptake and pricing. Financially, the company has one revenue-generating product, has incurred significant losses since inception, and will need substantial additional capital or partnerships to fund clinical development and commercialization, leaving the stock exposed to volatile clinical and regulatory outcomes.